Angiotensin-(1-7) Mitigated Angiotensin II-induced Abdominal Aortic Aneurysms in Apolipoprotein E Knockout Mice.
To test the hypothesis that angiotensin-(1-7) [Ang-(1-7)] treatment may attenuate abdominal aortic aneurysm (AAA) via inhibiting vascular inflammation, extracellular matrix degradation and smooth muscle cells (SMCs) apoptosis, an animal model of AAA was established by angiotensin II (Ang II) infusion to apolipoprotein E-knockout (ApoE-/- ) mice. All mice and cultured SMCs or macrophages were divided into control, Ang II-treated, Ang II + Ang-(1-7)-treated, Ang II + Ang-(1-7) + A779-treated and Ang II + Ang-(1-7) + PD123319-treated groups, respectively. In the in vivo experiment, Ang-(1-7) treatment reduced the incidence and severity of AAA induced by Ang II infusion, and the mechanisms involved inhibited macrophage infiltration, attenuated expression of interleukin 6(IL-6), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein 1(MCP-1) and matrix metalloprotease 2(MMP2), as well as abated SMCs apoptosis in the abdominal aortic tissues. However, the addition of A779 or PD123319 treatment in these mice reversed Ang-(1-7)-mediated beneficial effects on AAA. In the in vitro experiment, Ang-(1-7) treatment mitigated the mRNA expression of IL-6, TNF-α and MCP-1 induced by Ang II stimulation in macrophages. In addition, Ang-(1-7) treatment significantly suppressed apoptosis and MMP2 expression and activity in Ang II-treated SMCs. The molecular mechanism may involve inhibition of extracellular signal-regulated kinase1/2 (ERK1/2) signaling pathways via Ang-(1-7) stimulation of Mas and angiotensin II type 2 receptors. Ang-(1-7) treatment attenuated Ang II-induced AAA via inhibiting vascular inflammation, extracellular matrix degradation and SMCs apoptosis. Ang-(1-7) may provide a novel and promising approach to the prevention and treatment of AAA.